Document:

EX-4.2

 Exhibit 4.2 

Execution Version 

Allena Pharmaceuticals, Inc. 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 1.      Definitions
	  	 	1	 
		
	 2.      Registration Rights
	  	 	5	 
	 2.1           Demand Registration
	  	 	5	 
	 2.2           Company Registration
	  	 	6	 
	 2.3           Form S-3
Registration
	  	 	6	 
	 2.4           Underwriting
Requirements
	  	 	7	 
	 2.5           Obligations of the
Company
	  	 	9	 
	 2.6           Furnish Information
	  	 	10	 
	 2.7           Expenses of
Registration
	  	 	10	 
	 2.8           Delay of
Registration
	  	 	11	 
	 2.9           Indemnification
	  	 	11	 
	 2.10        Reports Under Exchange Act
	  	 	13	 
	 2.11        Limitations on Subsequent Registration
Rights
	  	 	13	 
	 2.12        “Market Stand-Off Agreement
	  	 	14	 
	 2.13        Assignment of Registration Rights
	  	 	14	 
	 2.14        Restrictions on Transfer
	  	 	15	 
	 2.15        Termination of Registration Rights
	  	 	16	 
		
	 3.      Information and Observer Rights
	  	 	16	 
	 3.1           Delivery of Financial
Statements
	  	 	16	 
	 3.2           Inspection
	  	 	18	 
	 3.3           Observer Rights
	  	 	18	 
	 3.4           Termination of Information
and Observer Rights
	  	 	19	 
	 3.5           Confidentiality
	  	 	19	 
		
	 4.      Rights to Future Stock Issuances
	  	 	20	 
	 4.1           Right of First Offer
	  	 	20	 
	 4.2           Termination
	  	 	21	 
		
	 5.      Additional Covenants
	  	 	21	 
	 5.1           Insurance
	  	 	21	 
	 5.2           Employee Agreements
	  	 	21	 
	 5.3           Employee Stock and Option
Vesting
	  	 	21	 
	 5.4           Founder Stock and Option
Vesting
	  	 	22	 
	 5.5           Qualified Small Business
Stock
	  	 	22	 
	 5.6           Matters Requiring Preferred
Director Approval
	  	 	22	 
	 5.7           Meetings of the Board of
Directors
	  	 	23	 
	 5.8           Successor
Indemnification
	  	 	24	 
	 5.9           Board Expenses
	  	 	24	 
	 5.10        Termination of Covenants
	  	 	24	 
		
	 6.      Miscellaneous
	  	 	24	 
	 6.1           Successors and
Assigns
	  	 	24	 

  
 - i - 

					
	 6.2           Governing Law
	  	 	25	 
	 6.3           Counterparts
	  	 	25	 
	 6.4           Titles and Subtitles
	  	 	25	 
	 6.5           Notices
	  	 	25	 
	 6.6           Amendments and
Waivers
	  	 	25	 
	 6.7           Severability
	  	 	26	 
	 6.8           Aggregation of Stock
	  	 	26	 
	 6.9           Additional Investors
	  	 	27	 
	 6.10        Entire Agreement
	  	 	27	 
	 6.11        Dispute Resolution
	  	 	27	 
	 6.12        Delays or Omissions
	  	 	27	 
	 6.13        Acknowledgment
	  	 	27	 

 Schedule A – Schedule of Investors 

  
 - ii - 

 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 25th day of November,
2015 by and among Allena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (together with any subsequent investors, or transferees, who become parties hereto
as “Investors” pursuant to Section 6.9 below, the “Investors”). 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of Series A Preferred Stock, Series B
Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as
of November 6, 2014 between the Company and such Investors (the “Prior Agreement”); and 
 WHEREAS, the
Existing Investors are holders of at least 62.5% of the outstanding Series B Preferred Stock, and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights
granted to them under the Prior Agreement; and 
 WHEREAS, certain of the investors who are not Existing Investors (the
“New Investors”) and certain Existing Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date herewith between the Company and certain of the Investors (the “Purchase
Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding at least 62.5% of the outstanding
Series B Preferred Stock, and the Company; 
 NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement
shall be amended and restated, and the parties to this Agreement further agree as follows: 
 1. Definitions. For purposes of
this Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any other Person who or which, directly or
indirectly, controls, is controlled by, or is under common control with such specified Person, including without limitation any partner, officer, director, manager or employee of such Person and any venture capital or other investment fund now or
hereafter existing that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person, provided, however, that “Affiliate”
with respect to those Holders that are advisory clients of Fidelity shall include other funds and accounts managed by Fidelity. 
 1.2
“Common Stock” means shares of the Company’s common stock, par value $0.001 per share. 

  
 - 1 - 

 1.3 “Common Stock Director” means the director of the Company that the holders
of record of the Common Stock are entitled to elect exclusively and as a separate class pursuant to the Restated Certificate. 
 1.4
“Competitor” means any Person that the Board of Directors reasonably determines is a competitor of the Company; provided, however, that none of Frazier Healthcare Partners, Third Rock Ventures, Bessemer Venture
Partners, HBM BioCapital II LP, Pharmstandard International, S.A., the Wellington Investors, the Fidelity Investors, Partner Fund Management, L.P. nor any of their Affiliates (excluding such parties’ portfolio companies) is or shall be a
Competitor. 
 1.5 “Damages” means any loss, claim, damage, or liability (joint or several) to which a party hereto may
become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, claim, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged
untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or its agents or Affiliates) of the
Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.6 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for, Common
Stock, including options and warrants. 
 1.7 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder. 
 1.8 “Excluded Registration” means a registration relating either to the
sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan or to an SEC Rule 145 transaction; a registration on any form that does not include substantially the same information as would be required to
be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 1.9 “Fidelity” shall mean Fidelity Management & Research Company and any successor or affiliated investment
advisor to the Fidelity Investors (as defined below). 
 1.10 “Fidelity Investors” shall mean the Investors that are
advisory clients of Fidelity with respect to holdings of shares in the Company. For the sake of clarity, as of the date hereof, the Fidelity Investors are marked with an asterisk on Schedule A attached hereto. 

1.11 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the
Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

  
 - 2 - 

 1.12 “Founders” means Alexey Margolin and Robert Gallotto. 

1.13 “GAAP” means generally accepted accounting principles in the United States. 

1.14 “HBM Director” means the director designated by HBM BioCapital II LP pursuant to Section 1.2(a) of the Voting
Agreement. 
 1.15 “Holder” means any Investor holding Registrable Securities who is a party to this Agreement. 

1.16 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.17 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.18 “IPO” means a Qualifying Public Offering (as defined in the Restated Certificate). 

1.19 “Major Investor” means (i) any Investor that, individually or together with such Investor’s Affiliates, holds
at least 2,500,000 shares of Preferred Stock, (ii) each Wellington Investor that holds any shares of capital stock of the Company and (iii) any transferee of Preferred Stock transferred by a Major Investor if such transferee is an
Affiliate of such Major Investor and such transferee, individually or together with its Affiliates, holds at least 2,500,000 shares of Preferred Stock (in each of clauses (i) and (iii), as adjusted for any stock split, stock dividend,
combination, or other recapitalization or reclassification effected after the date hereof). 
 1.20 “New Securities” means,
collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or
exchangeable into or exercisable for such equity securities. 
 1.21 “Person” means any individual, corporation,
partnership, trust, limited liability company, association or other entity. 
 1.22 “Preferred Directors” means the
directors of the Company that the holders of record of the Preferred Stock are entitled to elect exclusively and as a separate class pursuant to the Restated Certificate. 

1.23 “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock, Series B Preferred Stock
and Series C Preferred Stock. 
 1.24 “Register,” “registered,” and “registration” refer
to a registration effected by preparing and filing a registration statement or similar document in compliance 

  
 - 3 - 

 
with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

1.25 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock held
by an Investor; (ii) any Common Stock, or any Common Stock issued or issuable upon conversion of any capital stock of the Company, in each case acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or
issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and
(ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the rights under Section 2 hereof are not assigned or any shares for which registration rights have terminated
pursuant to Section 2.15 of this Agreement. 
 1.26 “Registrable Securities then outstanding” means the number
of shares determined by adding the number of shares of Common Stock outstanding that are Registrable Securities and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities that are Registrable Securities.

 1.27 “Required Holders” means the holders of at least sixty percent (60%) of the Registrable Securities then
outstanding. 
 1.28 “Restated Certificate” means the Company’s Restated Certificate of Incorporation, as amended and
in effect from time to time. 
 1.29 “Restricted Securities” means the securities of the Company described in clauses (i),
(ii) and (iii) of Section 2.14(b) and which are required to bear the legend set forth in Section 2.14(b) hereof. 

1.30 “SEC” means the Securities and Exchange Commission. 

1.31 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.32 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.33 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.34 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except as provided in Section 2.7. 
 1.35
“Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001 per share. 

  
 - 4 - 

 1.36 “Series B Preferred Stock” means shares of the Company’s Series B
Preferred Stock, par value $0.001 per share. 
 1.37 “Series C Preferred Stock” means shares of the Company’s Series C
Preferred Stock, par value $0.001 per share. 
 1.38 “Voting Agreement” means the Second Amended and Restated Voting
Agreement by and among the Company, the Investors and the Key Holders (as defined therein), dated as of the date hereof, as amended and/or restated from time to time. 

1.39 “Wellington” shall mean Wellington Management Company LLP and any successor or affiliated registered investment advisor
to the Wellington Investors. 
 1.40 “Wellington Investors” shall mean any Investors advised or subadvised by Wellington or
one of its affiliates as of the date hereof. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) If at any time after the earlier of (i) three (3) years after the date of this Agreement or (ii) one hundred eighty
(180) days after the effective date of the registration statement for the IPO, the Company receives a request from the Required Holders that the Company file a Form S-1 registration statement with respect to at least 60% of the Registrable
Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $15,000,000), then the Company shall (i) within ten (10) days after the date such request is given, give
notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating
Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(b).

 (b) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors (the “Board of Directors”) it would be materially
detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business
purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any
time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the 

  
 - 5 - 

 
request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further
that the Company shall not register any securities for its own account or that of any other stockholder during such sixty (60) day period other than pursuant to a registration relating to the sale of securities to employees of the Company or a
subsidiary pursuant to a stock option, stock purchase, or similar plan; a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the
Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

(c) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 2.1
(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated
registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected one (1) registration pursuant to
Section 2.1; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.3. A registration
shall not be counted as “effected” for purposes of this Section 2.1 until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such
registration, do not pay the registration expenses therefor and, as a result, forfeit their right to one demand registration statement pursuant to Section 2.7, in which case such withdrawn registration statement shall be counted as
“effected” for purposes of this Section 2.1. 
 2.2 Company Registration. If the Company proposes to register
(including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash
(other than an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company
shall, subject to the provisions of Section 2.4, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw
any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses of such withdrawn
registration shall be borne by the Company in accordance with Section 2.7. 
 2.3 Form S-3 Registration. If the Company
receives a request from Holders of at least 40% of the Registrable Securities then outstanding that the Company effect a registration on Form S-3 with respect to all or a part of the Registrable Securities owned by such Initiating Holders, then the
Company shall: 
 (a) within ten (10) days after the date such request is given, give notice of the proposed registration to all
Holders other than the Initiating Holders (the “S-3 Notice”); and 

  
 - 6 - 

 (b) as soon as practicable, use its commercially reasonable efforts to effect such registration
as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other
Holders joining in such request as are specified in a request given to the Company within fifteen (15) days after the S-3 Notice is given; provided, however, that the Company shall not be obligated to effect any such registration
pursuant to this Section 2.3 (i) if Form S-3 is not then available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to and requesting inclusion in
such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of Selling Expenses) of less than $2,000,000; (iii) if the Company furnishes to the Holders a certificate
signed by the chief executive officer of the Company stating that in the good-faith judgment of the Board of Directors, it would be materially detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such
time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than 60 days after receipt of the request of the Initiating Holders under this Section 2.3;
provided, however, that the Company shall not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of
any other stockholder during such sixty (60) day period other than pursuant to a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being
registered is Common Stock issuable upon conversion of debt securities that are also being registered; or (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected two
(2) registrations on Form S-3 for the Holders pursuant to this Section 2.3. 
 (c) Registrations effected pursuant to this
Section 2.3 shall not be counted as demands for registration or registrations effected pursuant to Section 2.1, provided, however, that if the Company is eligible to register the Registrable Securities on Form
S-3, the Company may effect a registration pursuant to Section 2.1 on Form S-3. 
 2.4 Underwriting Requirements. 

(a) If, pursuant to Section 2.1 or Section 2.3, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1(a) or Section 2.3, and the Company shall include such information in
the Demand Notice or the S-3 Notice, as the case may be. The underwriter will be selected by the Initiating Holders, subject only to the reasonable approval of the Company. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.5(e)) enter into an underwriting agreement in customary form with the managing underwriter(s) selected for such
underwriting. Notwithstanding any other provision of 

  
 - 7 - 

 
this Section 2.4, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten,
then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among all
Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other portion as shall mutually be agreed to by all such selling
Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To
facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. In no
event shall any Registrable Securities be excluded from such offering unless all other stockholders’ securities have been first excluded. If the underwriters determine that less than all of the Registrable Securities requested to be registered
can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other
proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the
nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced below twenty-five percent (25%) of the total number of securities included in such offering,
unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering or
(ii) notwithstanding (i) above, any Registrable Securities described in Section 1.22(i) be excluded from such underwriting unless all Registrable Securities described in Section 1.22(ii) are first excluded from such
offering. For purposes of the provision in this Section 2.4(b) concerning apportionment, for any selling stockholder that is a Holder and a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be
deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate 

  
 - 8 - 

 
number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Section 2.1 and Section 2.3, a registration shall not be counted as “effected” if, as a
result of an exercise of the underwriter’s cutback provisions in Section 2.4(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration
statement are actually included. 
 2.5 Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC
a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of at least a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with
applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred twenty (120) additional days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;

 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in
any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering; 

  
 - 9 - 

 (f) use its commercially reasonable efforts to cause all such Registrable Securities covered by
such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent in connection with any such registration statement; 
 (i) notify each selling
Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 2.6 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.7 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to
exceed $50,000, of one counsel for the selling Holders, shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Section 2.1 or Section 2.3 if the registration request is subsequently withdrawn at the request of the Required Holders (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable
Securities that were to be included in the withdrawn registration), unless the Required Holders agree to forfeit their right to one registration pursuant to Section 2.1 or Section 2.3, as the case may be; provided
further that if, at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the
request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not 

  
 - 10 - 

 
forfeit their right to one registration pursuant to Section 2.1 or Section 2.3. All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.8 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.9 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating any matter or defending any proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.9(a) shall not apply to amounts paid in settlement of any such investigation or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person intended to be indemnified pursuant to this Section 2.9(b) any legal or other expenses
reasonably incurred thereby in connection with investigating any matter or defending any proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.9(b) shall not apply to amounts paid in settlement of any such investigation or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further
that in no event shall any indemnity under this Section 2.9(b) exceed the 

  
 - 11 - 

 
proceeds from the offering (net of any Selling Expenses) received by such Holder, except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.9 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.9, give the
indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.9, to the extent that such failure materially prejudices the indemnifying party’s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.9. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.9 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.9 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.9, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case,
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a
Holder’s liability pursuant to this 

  
 - 12 - 

 
Section 2.9(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.9(b), exceed the proceeds from the offering (net of any Selling
Expenses) received by such Holder, except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing,
to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the
underwritten public offering, the obligations of the Company and Holders under this Section 2.9 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise
shall survive the termination of this Agreement. 
 2.10 Reports Under Exchange Act. With a view to making available to the Holders
the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent applicable, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies);
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or
regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to such Form S-3 (at any time after the
Company so qualifies to use such form). 
 2.11 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Required Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder
(i) to include such securities in any 

  
 - 13 - 

 
registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such
securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) to demand registration of any securities held by such holder or prospective holder; provided that this limitation shall
not apply to any Additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 
 2.12
“Market Stand-Off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days) or, if required by such underwriter, such longer period of time as is necessary to enable such underwriter to issue a
research report or make a public appearance that relates to an earnings release or announcement by the Company within fifteen (15) days before or after the date that is one hundred eighty (180) days after the effective date of the
registration statement relating to such offering, but in any event not to exceed two hundred ten (210) days following the effective date of the registration statement relating to such offering, (i) lend; offer; pledge; sell; contract to
sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The
foregoing provisions of this Section 2.12 shall apply only to the IPO, shall not apply to shares of Common Stock acquired in the IPO or in the open market following the IPO , shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (assuming full
conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) are subject to the same restrictions. The underwriters in connection with the IPO are intended third party beneficiaries of this
Section 2.12 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in
the IPO that are substantially consistent with this Section 2.12 or that are necessary to give further effect thereto. If any of the obligations described in this Section 2.12 are waived or terminated with respect to any of
the securities of any such Holder, officer, director or greater than one-percent stockholder (in any such case, the “Released Securities”), the foregoing provisions shall be waived or terminated, as applicable, to the same extent
and with respect to the same percentage of securities of each Holder as the percentage of Released Securities represent with respect to the securities held by the applicable Holder, officer, director or greater than one-percent stockholder. 

2.13 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 2 may be assigned (but only with all related obligations) by a Holder to a transferee of such Registrable Securities that (i) is an Affiliate, partner, member, limited partner, retired partner, retired member, or stockholder
of a 

  
 - 14 - 

 
Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after
such transfer, holds at least 1,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) or, if less, all of the Registrable
Securities held by such Holder; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such registration rights are being transferred; (y) such transferee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.12; and
(z) the transferee is not, in the determination of the Board of Directors, a direct or indirect competitor of the Company. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a
transferee (1) that is an Affiliate, limited partner, retired partner, member, retired member, or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual
Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder. 
 2.14
Restrictions on Transfer. 
 (a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise
transferred, and the Company shall not recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this
Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144 to be bound by the terms of this Agreement. 

(b) Each certificate representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities
issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of
Section 2.14(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 
 THE SHARES REPRESENTED
BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH
THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 - 15 - 

 The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent
of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.14. 
 (c) The
holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities,
unless there is in effect a registration statement under the Securities Act covering the proposed transaction, or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such
Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be
accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed
transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not
result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the
Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with Rule 144 or (y) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Section 2.14(c).
Each certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in
Section 2.14(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 
 2.15 Termination of Registration Rights. The right of any Holder to request registration or inclusion of
Registrable Securities in any registration pursuant to Section 2.1, Section 2.2, or Section 2.3 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; and 

(b) the fifth anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that such Major Investor
is not a Competitor of the Company: 

  
 - 16 - 

 (a) as soon as practicable, but in any event within ninety (90) days after the end of each
fiscal year of the Company, (i) a balance sheet as of the end of such year; (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the
comparable amounts for the prior year and as included in the Budget (as defined in Section 3.1(e)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of
funds for such year; and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company;

 (b) as soon as practicable, but in any event within forty five (45) days after the end of each of the first three (3) quarters
of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in
accordance with GAAP (except that the financial report may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock
issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet
issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified on behalf of the Company by the chief financial officer or
chief executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event within thirty
(30) days after the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance
with GAAP (except that the financial report may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets
prepared by the Company; 
 (f) with respect to the financial statements called for in Section 3.1(a),
Section 3.1(b) and Section 3.1(d), an instrument executed on behalf of the Company by the chief operating officer and chief executive officer of the Company certifying that such financial statements were prepared in
accordance with GAAP consistently applied with prior practice for 

  
 - 17 - 

 
earlier periods (except as otherwise set forth in Section 3.1(b) and Section 3.1(d)) and fairly present the financial condition of the Company and its results of operation
for the periods specified therein; and 
 (g) such other information relating to the financial condition, business, prospects, or corporate
affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company
reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its
commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit
each Major Investor (provided that such Major Investor is not a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the
Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to
this Section 3.2 to provide access to any information that it reasonably considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the
disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 3.3 Observer Rights.
Each of (w) Third Rock Ventures II, L.P., (x) Frazier Healthcare VI, L.P., (y) Bessemer Venture Partners VII L.P., Bessemer Venture Partners VII Institutional L.P. and BVP VII Special Opportunity Fund L.P. and (z) HBM BioCapital
II LP, shall be entitled to have a representative attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, after the Company receives prior notice regarding the identity of the representative to attend
such meetings, the Company shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided,
however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any
information and to exclude such representative from 

  
 - 18 - 

 
any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in
disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. 
 3.4
Termination of Information and Observer Rights. The covenants set forth in Sections 3.1, 3.2 and 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO,
(ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Restated
Certificate or other Sale of the Company (as defined in the Voting Agreement); provided, that, with respect to (iii), the covenants set forth in Sections 3.1 and 3.2 shall only terminate if the consideration received by
the Holders in such Deemed Liquidation Event or other Sale of the Company is in the form of cash and/or marketable securities unless the Holders receive financial information and inspection rights from the acquiring company or other successor to the
Company comparable to those set forth in Sections 3.1 and 3.2, whichever event occurs first. 
 3.5 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms
of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by
a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any Affiliate, partner (and partners of such partner), member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course
of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law,
provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing, in the case of any Wellington Investor, such
Wellington Investor may identify the Company and the value of such Wellington Investor’s security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies and respond to routine
examinations, demands, requests or reporting requirements of a regulator without prior notice to or consent from the Company. For avoidance of doubt, nothing contained in this Section 3.5 shall in any way restrict or impair the
obligations of Fidelity to report the investment of its advisory clients (as Investors hereunder) in the Company in accordance with applicable laws and regulations, without any requirement of prior notice to the Company. 

  
 - 19 - 

 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to the Investors who are accredited investors in accordance with Rule 501(a) of the Securities Act (the “Offerees”). Any Offeree
shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate. 

(a) The Company shall give notice (the “Offer Notice”) to each Offeree, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Offeree may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the shares of Common Stock issued or issuable upon conversion of the Preferred Stock held by
such Offeree bears to the total Common Stock issued or issuable upon conversion of all Preferred Stock held by all of the Offerees. At the expiration of such twenty (20) day period, the Company shall promptly notify each Offeree that elects to
purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Offeree’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice,
each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Offerees were entitled to subscribe but that
were not subscribed for by the Offerees which is equal to the proportion that the Preferred Stock (calculated for this purpose as if fully converted into shares of Common Stock) held by such Fully Exercising Investor bears to the Common Stock issued
and held, or issuable upon conversion of the Preferred Stock then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within sixty
(60) days after the date that the Offer Notice is given. 
 (c) If all New Securities referred to in the Offer Notice are not elected
to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed
portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to such Person(s) than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New
Securities within such period, or if such agreement is not consummated within thirty (30) days after the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first
reoffered to the Offeree in accordance with this Section 4.1. 
 (d) The right of first offer in this Section 4.1
shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; (iii) the issuance of securities pursuant to the conversion, exercise, or

  
 - 20 - 

 
exchange of Derivative Securities outstanding on the date hereof; (iv) the issuance of securities in connection with a bona fide acquisition by the Company, whether by merger, consolidation,
purchase of assets, exchange of stock, or otherwise approved by the Board of Directors, including the Preferred Directors; (v) the issuance of stock or Derivative Securities to Persons with which the Company has business relationships;
provided that such issuances are for other than primarily capital-raising purposes and are approved by the Board of Directors, including the Preferred Directors; (vi) securities of the Company that otherwise are excluded by the
affirmative vote or consent of the Board of Directors, including the Preferred Directors; or (vii) the issuance of shares of Series B Preferred Stock pursuant to the Purchase Agreement. 

4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate, (iii) upon the closing of another Sale of the Company (as defined in the
Voting Agreement), or (iv) upon the liquidation of the Company, whichever event occurs first. 
 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to maintain, from financially sound and reputable insurers,
(a) Directors and Officers insurance, (b) product liability insurance, and (c) employment practices liability insurance, each in an amount and on terms and conditions satisfactory to the Board of Directors, until such time as the
Board of Directors determines that any such insurance policies should be discontinued. No such policy shall be cancelable by the Company without prior approval of the Board of Directors, including a majority of the Preferred Directors then in
office. 
 5.2 Employee Agreements. The Company will cause (i) each Person now or hereafter employed by it or by any subsidiary
(or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement in a form substantially as approved by the Board of Directors, including a majority of the
Preferred Directors then in office; and (ii) each key employee designated by the Board of Directors or the compensation committee thereof to enter into a noncompetition and nonsolicitation agreement in a form substantially as approved by the
Board of Directors, including a majority of the Preferred Directors then in office, in addition to their entering into the agreement described in clause (i) above. In addition, the Company shall not amend, modify, terminate, waive, or otherwise
alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the approval of the Board of Directors, including a majority of the Preferred Directors then in
office. 
 5.3 Employee Stock and Option Vesting. Unless otherwise approved by the Board of Directors, including the affirmative vote
of a majority of the Preferred Directors then in office, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be
required to execute restricted stock or option agreements, as applicable, providing for (a) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve
(12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months 

  
 - 21 - 

 
and (b) a market stand-off provision substantially similar to that in Section 2.12. In addition, unless otherwise approved by the Board of Directors, including a majority of the
Preferred Directors then in office, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a
holder of restricted stock. 
 5.4 Founder Stock and Option Vesting. Unless otherwise approved by the Board of Directors, including
the affirmative vote of a majority of the Preferred Directors, if a Founder purchases, receives an option to purchase, or receives an award of shares of the Company’s capital stock after the date hereof, such Founder shall be required to
execute a restricted stock or option agreement, as applicable, providing for vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months; provided, however, that such vesting may be subject to acceleration of such shares on an event
constituting a Change of Control of the Company (as such term is defined in the Stock Restriction Agreements by and between the Company and each of the Founders). 

5.5 Qualified Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Preferred Stock issued
pursuant to the Purchase Agreement, as well as any shares into which such shares are converted, within the meaning of section 1202(f) of the Internal Revenue Code (the “Code”), to constitute “qualified small business
stock” as defined in section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors determines, in its good-faith business judgment, that such qualification is inconsistent
with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under section 1202(d)(1)(C) of the Code and the regulations
promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and
what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s
possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in section 1202(c) of the Code.

 5.6 Matters Requiring Preferred Director Approval. So long as the holders of Preferred Stock are entitled to elect at least one
(1) Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without the approval of the Board of Directors, which approval must include the affirmative vote of at least three (3) of the
four (4) Preferred Directors (or, if less than four (4) Preferred Directors are then in office, by the affirmative vote of at least a majority of the Preferred Directors): 

(a) Make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership or other entity unless it is wholly owned by the Company; 

  
 - 22 - 

 (b) Make, or permit any subsidiary to make, any loan or advance to any Person, including,
without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors;

 (c) Guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) Make any investment inconsistent with any
investment policy approved by the Board of Directors; 
 (e) Incur any aggregate indebtedness for borrowed money in excess of $50,000 that
is not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f) Otherwise enter into or be a party to any transaction with any director, officer or employee of the Company or any “associate”
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for (i) transactions contemplated by this Agreement, the Purchase Agreement and any agreement in effect on the date hereof and listed in the Disclosure
Schedule to the Purchase Agreement; (ii) transactions resulting in payments to or by the Company in an aggregate amount less than $60,000 per year; (iii) compensation arrangements and equity incentive awards approved by the Board of
Directors or the compensation committee thereof; and (iv) transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a
majority of the Board of Directors; 
 (g) Hire, terminate or change the compensation of any “executive officer” (as defined in
Rule 3b-7 promulgated under the Exchange Act), including approving any option grants or stock awards to executive officers or amend any restricted stock agreements between the Company and any Investor in effect on the date hereof; 

(h) Materially change the principal business of the Company, enter new lines of business or exit the current line of business; 

(i) Sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary
course of business; or 
 (j) Enter into any corporate strategic relationship involving the payment, contribution, or assignment by the
Company or to the Company of money or assets greater than $250,000. 
 5.7 Meetings of the Board of Directors. Unless otherwise
determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly or as otherwise approved by the Board of Directors. The Company shall cause to be established, as soon as practicable after
the date hereof, and will maintain, a compensation committee which shall consist of at least three (3) directors, at least one of whom shall be the HBM Director. 

  
 - 23 - 

 5.8 Successor Indemnification. If the Company or any of its successors or assignees
(i) consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to any
Person, then, and in each such case, to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of
Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Restated Certificate, or elsewhere, as the case may be. 

5.9 Board Expenses. The Company shall reimburse the nonemployee members of the Board of Directors (and any observers pursuant to
Section 3.3) for all reasonable out-of-pocket travel or other expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors or other Company business. 

5.10 Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.9, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate, (iii) upon the closing of any
other Sale of the Company (as defined in the Voting Agreement) whichever event occurs first, or (iv) upon the liquidation of the Company. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate, partner, member, limited partner, retired
partner, retired member, or stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) such transfer is
made pursuant to and in compliance with Section 2.13; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee
and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement,
including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate, limited partner, retired partner,
member, retired member, or stockholder of a Holder: (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated
together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights,
receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement shall inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided herein. 

  
 - 24 - 

 6.2 Governing Law. This Agreement and any controversy arising out of or relating to this
Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the
internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 
 6.3 Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile, electronic mail
(including pdf) or other transmission method and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices, requests, and other communications given or made pursuant to
this Agreement shall be in writing and shall be deemed effectively given (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the
recipient, and if not so confirmed, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a
nationally recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties only at their addresses as set forth on the signature pages hereto, or to such
email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy shall also be sent to Michael H. Bison, Esq., Goodwin Procter
LLP, 53 State Street, Boston, MA 02109 Tel: (617) 570-1000, Fax: (617) 523-1231, if notice is given to Partner Fund Management, L.P., a copy shall also be given to Stephen M. Osborn, Esq., Osborn McDerby LLP, 333 Bush Street, San
Francisco, CA 94563, Tel: (415) 655-3707, Fax: (415)373-6821. 
 6.6 Amendments and Waivers. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least sixty percent
(60%) of the shares of Preferred Stock then outstanding (voting as a single class on an as-converted basis); provided that (i) Sections 2.12, 3.1, 3.2 and 3.4 shall not be modified, supplemented,
amended or waived, in whole or in part, in a manner that adversely affects the Wellington Investors, without the prior written consent of the Wellington Investors holding a majority of the Registrable Securities held by all Wellington Investors and
(ii) the Company may in its sole discretion waive compliance with Section 2.14(c) (and the Company’s failure to object promptly in writing to a proposed assignment allegedly in violation of Section 2.14(c) shall be
deemed to be a waiver). Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be 

  
 - 25 - 

 
deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase
securities in such transaction). No amendment to Section 2.12 that adversely affects a New Investor and does not so similarly adversely affect the Existing Investors will be enforceable against such New Investor without the consent of
such New Investor. In the event that any Investor who affirmatively consented in writing to a waiver of the right of first offer in Section 4.1 purchases New Securities in the financing for which such right of first offer in
Section 4.1 was waived on behalf of the Investors, the Company shall give notice to each other Investor who did not affirmatively consent in writing to such waiver (each such Investor, a “Non-Consenting Investor”) within
thirty (30) days after the issuance of the New Securities in the financing that were the subject of such waiver. Such notice shall describe the type, price, and terms of such New Securities. Each Non-Consenting Investor shall have twenty
(20) days from the date notice is sent to such Non-Consenting Investor to elect to purchase up to the number of such New Securities that will enable such Non-Consenting Investor to maintain its percentage ownership of the fully diluted equity
of the Company (including in such calculation the New Securities previously issued in reliance upon the waiver and any New Securities to be acquired by the Non-Consenting Investors in accordance with this Section 6.6) (the “Fully
Diluted Equity”) at the same level as the percentage such Non-Consenting Investor held immediately prior to the issuance of the New Securities previously issued in the financing in reliance upon the waiver. For this purpose, the percentage
ownership of the Fully Diluted Equity of a Non-Consenting Investor is a fraction, expressed as a percentage, of which the numerator is (x) the number of shares of Common Stock held by such Non-Consenting Investor plus the number of shares of
Common Stock issuable upon conversion of the Preferred Stock held by such Non-Consenting Investor and (y) the denominator of which is the number of shares of Common Stock outstanding (assuming conversion of all then outstanding shares of
Preferred Stock). The closing of any such sale pursuant to this Section 6.6 shall occur within sixty (60) days after the date the notice referred to above is sent to the Non-Consenting Investors. The Company shall give prompt notice
of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

  
 - 26 - 

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if
the Company issues additional shares of the Company’s Series B Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for
such joinder to this Agreement by such additional Holder, so long as such additional Holder has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, all
provisions of, rights granted and covenants made the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect, including, without limitation, all rights of first refusal and any notice
period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement and the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of
no further force or effect. 
 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the
jurisdiction of the state courts of the Commonwealth of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon
this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the Commonwealth of Massachusetts or the United States District Court for the District of
Massachusetts, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that
its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof
may not be enforced in or by such court. 
 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy
accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.13
Acknowledgment. 
 (a) The Company acknowledges that the Investors are in the business of venture capital investing and therefore
review the business plans and related proprietary 

  
 - 27 - 

 
information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude
or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

(b) The Company acknowledges that each of Wellington Management Company LLP and Partner Fund Management, L.P. is in the business of providing
investment management services for its investment advisory clients and therefore reviews the financial information, business plans and proprietary and other information of many enterprises, including enterprises that may have products or services
which compete directly or indirectly with those of the Company. Nothing in this agreement shall preclude or in any way restrict Wellington Management Company LLP or Partner Fund Management, L.P. from investing on behalf of its investment advisory
clients, whether or not such enterprise has products or services which compete with those of the Company. The Company further acknowledges that each of Wellington Management Company LLP and Partner Fund Management, L.P., on behalf of certain of its
investment advisory clients, trades in securities in the public markets and that Wellington Management Company LLP’s or Partner Fund Management, L.P.’s access to the Company’s confidential information shall not preclude or in any way
restrict Wellington Management Company LLP’s or Partner Fund Management, L.P.’s ability to trade securities in the public markets on behalf of its investment advisory clients, nor shall the access to such confidential information by any
investment advisory client preclude or in any way restrict such investment advisory client’s ability to trade securities in the public markets. For purposes of clarity, the term “investment advisory clients” includes, without
limitation, the Wellington Investors. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 28 - 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

							
	Company:	 		 	ALLENA PHARMACEUTICALS, INC.
				
		 		 	By:	 	/s/ Alexey Margolin
		 		 	Name:	 	Alexey Margolin
		 		 	Title:	 	President and Chief Executive Officer
		 		 	Address:	 	 One Newton Executive Park, Suite 202
 Newton,
MA 02462

 [Signature Page to Second Amended and Restated Investors’ Right Agreement] 

									
	Investors:	 		 		 	FRAZIER HEALTHCARE VI, L.P.
					
		 		 		 	By:	 	FHM VI, LP, its general partner
					
		 		 		 	By:	 	FHM VI, LLC, its general partner
					
		 		 		 	By:	 	/s/ James Topper
		 		 		 	Name:	 	James Topper
		 		 		 	Title:	 	Manager
					
		 		 		 	Address:	 	 601 Union Street, Suite 3200,
 Seattle, WA
98101

				
		 		 		 	THIRD ROCK VENTURES II, L.P.
					
		 		 		 	By:	 	Third Rock Ventures II GP, L.P., its general partner
					
		 		 		 	By:	 	TRV II GP, LLC, its general partner
					
		 		 		 	By:	 	/s/ Kevin Gillis
		 		 		 	Name:	 	 Kevin Gillis

		 		 		 	Title:	 	Manager
					
		 		 		 	Address:	 	 29 Newbury Street
 Boston, MA
02116

				
		 		 		 	BESSEMER VENTURE PARTNERS VII L.P.
				
		 		 		 	BESSEMER VENTURE PARTNERS VII INSTITUTIONAL L.P.
				
		 		 		 	BVP VII SPECIAL OPPORTUNITY FUND L.P.
					
		 		 		 	By:	 	Deer VII & Co. L.P., their General Partner
					
		 		 		 	By:	 	Deer VII & Co. Ltd., its General Partner
					
		 		 		 	By:	 	/s/ Scott King
		 		 		 	Name:	 	 Scott King

		 		 		 	Title:	 	 General Counsel

					
		 		 		 	Address:	 	 c/o Bessemer Venture Partners
 1865 Palmer
Avenue Suite 104
 Larchmont, NY 10538
 Tel: 914-833-5300

Email: transactions@bvp.com

 [Signature Page to Second Amended and Restated Investors’ Right Agreement] 

 
			
	Pharmstandard International, S.A.
		
	By: 	 	/s/ Eriks Martinovskis
	Name:	 	Eriks Martinovskis
	Title:	 	Director
		
	Address:	 	 Pharmstandard International, SA.
 10A, rue
Henri Schnadt
 L-2530, Luxembourg
 Grand-Duchy of
Luxembourg

 [Signature Page to Second Amended and Restated Investors’ Right Agreement] 

 Fidelity Adviser Series VII: Fidelity Advisor Biotechnology Fund 

 

			
	By: 	 	/s/ Stacie M. Smith
	Name:	 	Stacie M. Smith
	Title: 	 	Authorized Signatory

 Address: 
 State Street
Bank & Trust 
 PO Box 5756 
 Boston, Massachusetts
02206 
 Attn: Bangle & Co fbo Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund 

Email: SSBCORPACTIONS@.StateStreet.com 
 Fax number: 617-988-9110

 Fidelity Select Portfolios: Biotechnology Portfolio 
  

			
	By: 	 	/s/ Stacie M. Smith
	Name:	 	Stacie M. Smith
	Title: 	 	Authorized Signatory

 Address: 
 Brown Brothers
Harriman & Co. 
 525 Washington Blvd 
 Jersey City NJ
07310 
 Attn: Michael Lerman 15th Floor 
 Corporate Actions

 Email: michael.lerman@bbh.com 
 Fax number: 617 772-2418 

[Signature Page to Second Amended and Restated Investors’ Right Agreement] 

 Hadley Harbor Master Investors (Cayman) L.P. 

By: Wellington Management Company LLP, as investment adviser 
  

			
	By: 	 	/s/ Emily Babalas
	Name:	 	Emily Babalas
	Title:	 	Managing Director and Counsel

 Address: 
 Hadiey Harbor Master
Investors (Cayman) L.P. 
 c/o Wellington Management Company LLP 

Attention: Legal and Compliance Department 
 280 Congress Street

 Boston, MA 02210 
 Facsimile Number: 617-289-5699 

Email: seclaw@wellington.coin 
 [Signature Page to
Second Amended and Restated Investors’ Right Agreement] 

 
			
	PFM Healthcare Emerging Growth Master Fund, L.P., by Partner Fund Management, L.P., its investment adviser
		
	By:  	 	/s/ Yuan DuBord
	Name:	 	Yuan DuBord
	Title:	 	Authorized Signatory

  

	
	 Address:
 c/o Partner Fund Management, L.P,

4 Embarcadero Center, Suite 3500
 San Francisco, CA
94111

	
	PFM Healthcare Opportunities Master Fund, L.P., by Partner Fund Management, L.P., its investment adviser

  

			
	By:  	 	/s/ Yuan DuBord
	Name:	 	Yuan DuBord
	Title:	 	Authorized Signatory

  

	
	 Address:
 c/o Partner Fund Management, L.P,

4 Embarcadero Center, Suite 3500
 San Francisco, CA
94111

	
	Partner Investments, L.P., by Partner Investment Management, L.P., its investment adviser

  

			
	By:  	 	/s/ Yuan DuBord
	Name:	 	Yuan DuBord
	Title:	 	Authorized Signatory

  

	
	 Address:
 c/o Partner Fund Management, L.P.

4 Embarcadero Center, Suite 3500
 San Francisco, CA
94111

 [Signature Page to Second Amended and Restated Investors’ Right Agreement] 

 HBM BioCapital II LP 
  

									
	By: HBM BioCapital II Management Ltd, its general partner	 		 	
					
	By:	 	/s/ Mathew Hague	 		 	By:	 	/s/ Michael Doherty
	Name:	 	Mathew Hague	 		 	Name:	 	Michael Doherty
	Title:	 	Authorized Signatory	 		 	Title:	 	Authorized Signatory
					
		 		 		 	Date:	 	December 17, 2015

 Address: 
 HBM BioCapital II
Management Ltd. 
 (General Partner) 
 Michael Doherty 

c/o Aztec Financial Services (Jersey) Limited 
 Aztec Group House
11-15 Seaton Place 
 St Helier JE4 OQH, Jersey 

Michael.Doherty@aztecgroup.co.uk 
 With a copy to (which shall
not constitute notice): 
 Mehdi Khodadad 
 Cooley LLP 

3175 Hanover Street 
 Palo Alto, CA 94304-1130 

Fax: 650/849-7400 
 Email: mkhodadad@cooley.com 

[Signature Page to Second Amended and Restated Investors’ Right Agreement] 

 SCHEDULE A 

Investors 
 Frazier Healthcare VI, L.P.

 Third Rock Ventures II, L.P. 
 Bessemer Venture Partners VII
L.P. 
 Bessemer Venture Partners VII Institutional L.P. 
 BVP
VII Special Opportunity Fund L.P. 
 HBM BioCapital II LP 

Pharmstandard International, S.A. 
 PFM Healthcare Emerging Growth
Master Fund, L.P. 
 PFM Healthcare Opportunities Master Fund, L.P. 

Partner Investments, L.P. 
 Fidelity Adviser Series VII: Fidelity
Advisor Biotechnology Fund* 
 Fidelity Select Portfolios: Biotechnology Portfolio* 

Hadley Harbor Master Investors (Cayman) L.P.EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM
AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO
PURCHASE STOCK 
 Company: Allena Pharmaceuticals, Inc., a Delaware corporation 

Number of Shares: As set forth in Paragraph A below 

Type/Series of Stock: Series C Preferred Stock, $0,001 par value per share 

Warrant Price: $2.65 per Share, subject to adjustment 

Issue Date: May 2, 2016 
 Expiration Date:
May 1, 2026            See also Section 5.1(b). 
 Credit Facility:
This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Second Amendment, of even date herewith, to that certain Loan and Security Agreement dated August 18, 2014, between Silicon Valley
Bank and the Company, as amended (collectively, and as may be further amended and/or modified and in effect from time to time, the “Loan Agreement”).  

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any successor or permitted assignee or
transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase up to such number of fully paid and non-assessable shares of the above-stated Type/Series of Stock (the
“Class”) of the above-named company (the “Company”) as determined pursuant to Paragraph A below, at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to
Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant to its parent
company, SVB Financial Group. 
 A. Number of Shares. Upon the making of the 2016 Term A Loan Advance (as defined in the Loan
Agreement), if any, this Warrant automatically shall become exercisable for 28,302 shares of the Class, subject to adjustment from time to time (including, without limitation, in connection with events occurring prior to the making of such 2016
Term Loan A Advance) in accordance with the provisions of this Warrant. Upon the making of the 2016 Term B Loan Advance (as defined in the Loan Agreement), if any, this Warrant automatically shall become exercisable for an additional
9,434 shares of the Class, subject to adjustment from time to time (including, without limitation, in connection with events occurring prior to the making of such 2016 Term Loan B Advance) in accordance with the provisions of this Warrant. All
shares (if any) for which this Warrant shall become exercisable in accordance with this Paragraph A and as may be adjusted from time to time in accordance with the provisions of this Warrant are referred to herein collectively and cumulatively as
the “Shares.” 
 SECTION 1. EXERCISE. 

1.1 Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless 

 
Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form
of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 
 1.2 Cashless Exercise. On any
exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the
value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

 

	 	X =	Y(A-B)/A 

 where: 
  

	 	X =	the number of Shares to be issued to the Holder; 

  

	 	Y =	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price); 

 

	 	A =	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and 

  

	 	B =	the Warrant Price. 

 1.3 Fair Market Value. If the Company’s common stock is then
traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the
closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is
then traded in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for
the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If
the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. 

1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired (or surrendered pursuant to Section 1.2 to the extent applicable). 
 1.5 Replacement of
Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company 

  
 2 

 
for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a
majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by
the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b) Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the
Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in
accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares,
then this Warrant shall automatically be deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such
Cashless Exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other
securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately prior to such
Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. 
 (c) Upon
the closing of any Acquisition other than a Cash/Public Acquisition, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other
property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in
accordance with the provisions of this Warrant. 
 (d) As used in this Warrant, “Marketable Securities” means
securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in
connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, Holder would not

  
 3 

 
be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on
or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing
of such Acquisition. 
 SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property
which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of
shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise,
into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are
reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and
series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this
Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events. 

2.3 Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the event
that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in connection
with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all outstanding
shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the Warrant
Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time to time
in accordance with the provisions of this Warrant. 
 2.4 Adjustments for Diluting Issuances. Without duplication of any adjustment
otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Certificate of
Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 

  
 4 

 2.5 No Fractional Share. No fractional Share shall be issuable upon exercise of this
Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in
cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the
Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request
from Holder, furnish Holder with a certificate of its Chief Financial Officer or other officer performing similar duties, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such
adjustment. 
 SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b) All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The
Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise
in full of this Warrant and the conversion of the Shares into common stock or such other securities. 
 (c) The Company’s
capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the Issue Date. 
 3.2
Notice of Certain Events. If the Company proposes at any time to: 
 (a) declare any dividend or distribution upon the outstanding
shares of the Class or common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; 

(b) offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or
series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 
 (c) effect any reclassification, exchange,
combination, substitution, reorganization or recapitalization of the outstanding shares of the Class; 

  
 5 

 (d) effect an Acquisition or to liquidate, dissolve or wind up; or 

(e) effect an IPO; 
 then, in connection with
each such event, the Company shall give Holder: 
 (1) in the case of the matters referred to in (a) and (b) above,
at least seven (7) Business Days prior written notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which
the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any; 
 (2) in
the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class
will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with
such event giving rise to the notice); and 
 (3) with respect to the IPO, at least seven (7) Business Days prior
written notice of the date on which the Company proposes to file its registration statement in connection therewith. 
 The Company will also provide
information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide
access to any information the disclosure of which according to written advice given by the Company’s counsel to the Company (as certified to Holder in writing by the Company) would adversely affect the attorney-client privilege between the
Company and its counsel. 
 SECTION 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly
or indirectly, upon conversion of the Shares, if any) to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or
distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares (or the securities issuable, directly or indirectly, upon conversion of the Shares, if
any). 
 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has
received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity
to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed

  
 6 

 
such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s
investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) must be held indefinitely unless
subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under
the Act. 
 4.6 Market Stand-off Agreement. The Holder agrees that the Shares shall be subject to market stand-off provisions, the
same as those agreed to by Company stockholders in Section 2.12 of the Company’s Second Amended and Restated Investors’ Rights Agreement, dated November 25, 2015, as amended and/or restated and in effect from time to time. 

4.7 No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. 

SECTION 5. MISCELLANEOUS. 

5.1 Term; Automatic Cashless Exercise Upon Expiration. 

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 
 (b) Automatic Cashless Exercise
upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

  
 7 

 5.2 Legends. Each certificate evidencing Shares (and each certificate evidencing
securities issued, directly or indirectly, upon conversion of any Shares, if any) shall be imprinted with a legend in substantially the following form: 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED MAY 2, 2016, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the
transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act.
Additionally, the Company shall also not require an opinion of counsel if the Company and Holder agree that there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4 Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all of this
Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof as of the date of such transfer and
agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder
may transfer all or part of this Warrant or the Shares issued upon exercise of this Warrant (or the securities issued, directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such
transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant and/or Shares issued upon exercise of the Warrant (and/or securities issued, directly or indirectly, upon conversion of the Shares, if
any) being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant (and/or the stock certificates representing the Shares issued upon the exercise of this Warrant (or the
securities issued, directly or indirectly, upon conversion of the Shares, if any) being transferred) to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB
Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant or to which the Shares issued upon exercise of this Warrant (or the securities issued, directly or indirectly, upon conversion of
the Shares, if any) being transferred are then subject, as applicable. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s 

  
 8 

 
prior written consent, transfer this Warrant or any portion hereof, or any Shares issued, directly or indirectly, upon any exercise hereof, or any shares or other securities issued upon any
conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5 Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual
receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such
address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as
follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 
 SVB Financial Group 

Attn: Treasury Department 
 3003
Tasman Drive, HC 215 
 Santa Clara, CA 95054 

Telephone: (408) 654-7400 

Facsimile: (408) 988-8317 

Email address: derivatives@svb.com 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

Allena Pharmaceuticals, Inc. 

Attn: Chief Executive Officer 

One Newton Executive Park 

Suite 202 
 Newton, MA 02462

 Telephone: (617) 467-4577 

Facsimile: (617)916-1871 

Email: amargolin@allenapharma.com 

With a copy (which shall not constitute notice) to: 

On or prior to June 24, 2016 to: 

Goodwin Procter LLP 
 53 State
Street 
 Boston, MA 02109 

Attention: Michael H. Bison 

Facsimile: (617)523-1231 

Email: MBison@goodwinprocter.com 

Effective after June 24, 2016 to: 

  
 9 

 Goodwin Procter LLP 

100 Northern Avenue 
 Boston, MA
02210 
 Attention: Michael H. Bison 

Facsimile: (617) 523-1231 

Email: MBison@goodwinprocter.com 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. 

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts,
without giving effect to its principles regarding conflicts of law. 
 5.10 Headings. The headings in this Warrant are for purposes
of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11 Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 

[Remainder of page left blank intentionally] 

[Signature page follows] 

  
 10 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ALLENA PHARMACEUTICALS, INC.

			
		
	By:	 	/s/ Alexey Margolin

			
		
	Name:	 	Alexey Margolin

			
		 	(Print)
	Title:	 	CEO, President, Treasurer & Secretary
	
	“HOLDER”
	
	SILICON VALLEY BANK

			
		
	By:	 	 

			
		
	Name:	 	 

			
		 	(Print)
	Title:	 	

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ALLENA PHARMACEUTICALS, INC.

			
		
	By:	 	 

			
		
	Name:	 	 

			
		 	(Print)
	Title:	 	
	
	“HOLDER”
	
	SILICON VALLEY BANK

			
		
	By:	 	/s/ Matthew Griffiths

			
		
	Name:	 	Matthew Griffiths

			
		 	(Print)
	Title:	 	Vice President

 APPENDIX 1 

NOTICE OF EXERCISE 
 1. The
undersigned Holder hereby exercises its right to purchase                  shares of the Common/Series
             Preferred [circle one] Stock of
                             (the “Company”) in accordance with the attached
Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: 
  

	 	[    ]	check in the amount of $_payable to order of the Company enclosed herewith 

  

	 	[    ]	Wire transfer of immediately available funds to the Company’s account 

  

	 	[    ]	Cashless Exercise pursuant to Section 1.2 of the Warrant 

  

	 	[    ]	Other [Describe]
                                         
                                    

2. Please issue a certificate or certificates representing the Shares in the name specified below: 

 

					
			
	 	  	  
	  	 
		  	        Holder’s Name	  	
			
		  	  
	  	
			
		  	  
	  	
		  	        (Address)	  	

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

			
	HOLDER:
	
	 

 
			
		
	By:	 	 

 
			
		
	Name:	 	 

 
			
		
	Title:	 	 

 
			
		
	(Date):	 	 

  
 Appendix 1 

 SCHEDULE 1 

Company Capitalization Table 

See attached 

  
 Schedule 1 

 ALLENA PHARAMCEUTICALS 

Summary Capitalization Table 

As of March 31, 2016 
  

																																					
	 	  	Series A Preferred Stock	 	  	Series B Preferred Stock	 	  	Series C Preferred Stock	 	  	Total Capital (Fully Diluted)	 
	 	  	shares	 	  	cost basis	 	  	shares	 	  	cost basis	 	  	shares	 	  	cost basis	 	  	shares	 	  	ownership	 	 	cost basis	 
	 Preferred Shareholders
	  	 	18,367,344	 	  	$	18,000,000	 	  	 	19,841,270	 	  	$	25,000,000	 	  	 	20,000,000	 	  	$	53,000,000	 	  	 	58,208,614	 	  	 	79.91	% 	 	$	96,000,000	 
	 Frazier Healthcare
	  	 	6,122,448	 	  	 	6,000,000	 	  	 	4,629,630	 	  	 	5,833,334	 	  	 	1,061,904	 	  	 	2,814,046	 	  	 	11,813,982	 	  	 	16.22	% 	 	 	14,647,379	 
	 Third Rock ventures
	  	 	6,122,448	 	  	 	6,000,000	 	  	 	4,629,630	 	  	 	5,833,334	 	  	 	—  	 	  	 	—  	 	  	 	10,752,078	 	  	 	14.76	% 	 	 	11,833,334	 
	 Bessemer VP VII
	  	 	1,959,184	 	  	 	1,920,001	 	  	 	1,015,873	 	  	 	1,280,000	 	  	 	—  	 	  	 	—  	 	  	 	2,975,057	 	  	 	4.08	% 	 	 	3,200,001	 
	 Bessemer VP VII Institutional
	  	 	857,143	 	  	 	840,000	 	  	 	444,444	 	  	 	559,999	 	  	 	—  	 	  	 	—  	 	  	 	1,301,587	 	  	 	1.79	% 	 	 	1,400,000	 
	 BVP Special Opportunity Fund
	  	 	3,306,121	 	  	 	3,239,999	 	  	 	1,714,286	 	  	 	2,160,000	 	  	 	—  	 	  	 	—  	 	  	 	5,020,407	 	  	 	6.89	% 	 	 	5,399,999	 
	 HBM BioCapital II LP
	  	 	—  	 	  	 	—  	 	  	 	5,952,380	 	  	 	7,499,999	 	  	 	587,872	 	  	 	1,557,861	 	  	 	6,540,252	 	  	 	8.98	% 	 	 	9,057,860	 
	 Pharmstandard International S.A.
	  	 	—  	 	  	 	—  	 	  	 	1,455,027	 	  	 	1,833,334	 	  	 	1,980,105	 	  	 	5,247,278	 	  	 	3,435,132	 	  	 	4.72	% 	 	 	7,080,612	 
	 Fidelity Biotechnology Portfolio
	  	 	—  	 	  	 	—  	 	  				  				  	 	6,041,631	 	  	 	16,010,322	 	  	 	6,041,631	 	  	 	8.29	% 	 	 	16,010,322	 
	 Fidelity Advisor Biotechnology Fund
	  	 	—  	 	  	 	—  	 	  				  				  	 	1,505,538	 	  	 	3,989,676	 	  	 	1,505,538	 	  	 	2.07	% 	 	 	3,989,676	 
	 PFM Healthcare Opportunities Master Fund
	  	 	—  	 	  	 	—  	 	  				  				  	 	2,512,794	 	  	 	6,658,904	 	  	 	2,512,794	 	  	 	3.45	% 	 	 	6,658,904	 
	 PFM Healthcare Emerging Growth Master Fund
	  	 	—  	 	  	 	—  	 	  				  				  	 	774,365	 	  	 	2,052,067	 	  	 	774,365	 	  	 	1.06	% 	 	 	2,052,067	 
	 Partner Investments LP
	  	 	—  	 	  	 	—  	 	  				  				  	 	2,373,218	 	  	 	6,289,028	 	  	 	2,373,218	 	  	 	3.26	% 	 	 	6,289,028	 
	 Hadley Harbor Master Investors (Wellington)
	  	 	—  	 	  	 	—  	 	  				  				  	 	3,162,573	 	  	 	8,380,818	 	  	 	3,162,573	 	  	 	4.34	% 	 	 	8,380,818	 
	 Warrants to Purchase Series A
(SVB)1
	  	 	142,856	 	  				  				  				  				  				  	 	142,856	 	  	 	0.20	% 	 			
	 Common Shareholders
	  				  				  				  				  				  				  	 	14,491,942	 	  	 	19.89	% 	 			
	 Restricted Stock and Options Outstanding
	  				  				  				  				  				  				  	 	9,438,772	 	  	 	12.96	% 	 			
	 Common Stock
	  				  				  				  				  				  				  	 	543,197	 	  	 	0.75	% 	 			
	 Options Available for Grant
	  				  				  				  				  				  				  	 	4,509,973	 	  	 	6.19	% 	 			
	 Total
	  	 	18,510,200	 	  				  	 	19,841,270	 	  				  	 	20,000,000	 	  				  	 	72,843,412	 	  	 	100.00	% 	 			
		  	  
	  
	 	  				  	  
	  
	 	  				  	  
	  
	 	  				  	  
	  
	 	  	  
	  
	 	 			

  

	1 	Assumes exercise of SVB Series A Warrant for this calculation 

	  	Warrants issued to SVB in connection with Debt Financing 

  

					
		 	CONFIDENTIAL	 	
		 	NOT TO BE DISTRIBUTED WITHOUT PERMISSION	 	3/31/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]